Last reviewed 2026-04-23 · How we verify

YM177

YM177 is a glucagon-like peptide-1 (GLP-1) receptor agonist.

YM177 is a glucagon-like peptide-1 (GLP-1) receptor agonist. Used for Type 2 diabetes.

At a glance

Mechanism of action

It works by activating the GLP-1 receptor, which helps to regulate blood sugar levels and improve insulin sensitivity.

Approved indications

• Type 2 diabetes

Common side effects

• Nausea
• Vomiting
• Diarrhea

Key clinical trials

• Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma (PHASE2)
• Celecoxib, Durvalumab and Tremelimumab for the Treatment of Patients With Advanced or Metastatic Liver Cancer (PHASE2)
• Methotrexate, Erlotinib, and Celecoxib for the Treatment of Recurrent/Metastatic Oral Cavity Cancer in a Rural Midwest United States Population (PHASE2)
• Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of Patients With Metastatic or Unresectable Triple Negative Breast Cancer (PHASE1, PHASE2)
• Celecoxib Through Surgery and Radiation Therapy for the Treatment of Advanced Head and Neck Cancer (PHASE2)
• Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial (PHASE1)
• Chemokine Modulation Therapy and Standard Chemotherapy Before Surgery for the Treatment of Early Stage Triple Negative Breast Cancer (PHASE1)
• Chemokine Modulation Therapy and Pembrolizumab in Treating Participants With Metastatic Triple-Negative Breast Cancer (EARLY_PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.